Recent Updates
Recently added Catalysts
MPLT Positive Sentiment

Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study

Friday, August 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Segal Trials has announced its involvement in the Phase 2 ZEPHYR clinical trial, which evaluates MapLight Therapeutics' investigational therapy ML-007C-MA for acute schizophrenia. The trial's topline results were recently disclosed, showcasing the significance of this study in advancing treatment for schizophrenia. Segal Trials expresses pride in contributing to this clinical development.

Market Sentiment Analysis

POSITIVE FACTORS

  • Segal Trials reinforces its leadership in schizophrenia research.
  • Participation in the Phase 2 ZEPHYR study highlights their commitment.
  • Topline results from the study indicate progress in treatment options.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+154%
120-day peak, hindsight
Typical move
5.2%
average across 2 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
ML-007C-MA
Phase 2 · Schizophrenia

Full Press Release Details

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #ClinicalResearch--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia.MapLight Therapeutics recently announced topline results from the multicenter Phase 2 study. Segal Trials is proud to have contributed to this important clinical development program and congratulates

Frequently Asked Questions

What is the ZEPHYR study about?

The ZEPHYR study evaluates MapLight Therapeutics' therapy ML-007C-MA for acute schizophrenia.

Who participated in the Phase 2 ZEPHYR study?

Segal Trials participated in the Phase 2 ZEPHYR clinical trial.

What were the results of the ZEPHYR study?

Topline results from the ZEPHYR study were recently announced by MapLight Therapeutics.

What is ML-007C-MA?

ML-007C-MA is an investigational therapy targeting muscarinic receptors for schizophrenia.

ShareAdd on Google
Tags: MPLT Viatris Investor Conferences Healthcare Segal Trials MapLight Therapeutics ML-007C-MA acute schizophrenia clinical trial
Last updated: Aug 21, 2026

Biotech snapshot

Cash runway
$305M liquidity · $21M/mo burn
~14 mo
Low dilution risk
Lead asset
ML-007C-MAPhase 2
Schizophrenia →

Catalyst track record

+154%
best trade around MPLT's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MPLT.

See every catalyst's timing & PoA →